Alto Neuroscience (NYSE:ANRO) Sets New 1-Year High – Time to Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares reached a new 52-week high on Tuesday . The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 shares traded. The stock had previously closed at $34.28.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wolfe Research initiated coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. Wedbush raised their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Finally, Wall Street Zen raised shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.25.

Alto Neuroscience Price Performance

The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.43 billion, a PE ratio of -15.06 and a beta of 1.06. The stock has a 50-day simple moving average of $28.26 and a 200 day simple moving average of $23.90.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. Equities analysts expect that Alto Neuroscience, Inc. will post -2.68 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after buying an additional 211,222 shares during the period. Jennison Associates LLC acquired a new position in Alto Neuroscience during the 1st quarter worth about $8,687,000. Perceptive Advisors LLC boosted its holdings in Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after acquiring an additional 225,500 shares during the period. Orbimed Advisors LLC boosted its holdings in Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock valued at $3,765,000 after acquiring an additional 42,500 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in Alto Neuroscience in the 1st quarter valued at about $538,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.